PMN · Insider Trading
ProMIS Neurosciences Inc. Common Shares (ON)
Every open-market purchase and sale reported by PMN officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-10-06 | Ivana Rubino | Chief Commercial Officer | A | +80,000 deriv. | — |
| 2026-08-07 | Johanne Kaplan | Chief Development Officer | Buy | +2,280 | +$30.32K |
| 2026-08-07 | Johanne Kaplan | Chief Development Officer | Buy | +2,280 | +$30.32K |
| 2026-05-22 | Max A. Milbury | Principal Accounting Officer | A | +18,167 deriv. | — |
| 2026-05-22 | Neil K Warma | Chief Executive Officer | A | +160,000 deriv. | — |
| 2026-05-22 | Madge K. Shafmaster | Director | A | +16,500 deriv. | — |
| 2026-05-22 | Eugene Williams | Director | A | +16,500 deriv. | — |
| 2026-05-22 | Johanne Kaplan | Chief Development Officer | A | +50,000 deriv. | — |
| 2026-05-22 | William W Wyman | Director | A | +16,500 deriv. | — |
| 2026-05-22 | Josh Mandel-Brehm | Director | A | +16,500 deriv. | — |
| 2026-05-22 | Neil Cashman | Chief Scientific Officer | A | +50,000 deriv. | — |
| 2026-05-22 | Slanix Paul Alex | Director | A | +16,500 deriv. | — |
| 2026-04-23 | Patrick D. Kirwin | Director | Buy | +4,000 | +$45.32K |
| 2026-03-06 | Eugene Williams | Director | Buy | +2,000 | +$48.80K |
| 2026-03-04 | Eugene Williams | Director | Buy | +4,000 | +$92.42K |
| 2026-02-23 | Johanne Kaplan | Chief Development Officer | Buy | +1,629 | +$25.01K |
| 2026-02-05 | Max A. Milbury | — | A | +6,595 | +$80.00K |
| 2026-02-05 | Johanne Kaplan | Chief Development Officer | A | +2,060 | +$24.99K |
| 2026-02-05 | Patrick D. Kirwin | Director | A | +3,050 | +$37.00K |
| 2026-02-05 | Ally Bridge Group (NY) LLC | 10%+ Owner | Buy | +3,503,705 | +$42.50M |
| 2026-02-05 | Neil Cashman | Chief Scientific Officer | A | +4,122 | +$50.00K |
| 2026-02-05 | Neil K Warma | Chief Executive Officer | A | +6,183 | +$75.00K |
| 2025-10-24 | Ally Bridge Group (NY) LLC | 10%+ Owner | A | +200,000 deriv. | — |
| 2025-10-06 | Max A. Milbury | — | Buy | +30,392 | +$14.93K |
| 2025-09-30 | Jeremy M. Sclar 2012 Irrevocable Family Trust | 10%+ Owner | X | +2,093,022 | — |
| 2025-09-24 | Johanne Kaplan | Chief Development Officer | A | +165,000 deriv. | — |
| 2025-09-24 | Max A. Milbury | — | A | +60,000 deriv. | — |
| 2025-09-24 | Neil Cashman | Chief Scientific Officer | A | +165,000 deriv. | — |
| 2025-09-24 | Neil K Warma | Chief Executive Officer | A | +600,000 deriv. | — |
| 2025-09-24 | Larry Douglas Altstiel | Chief Medical Officer | A | +165,000 deriv. | — |
| 2025-09-08 | Jeremy M. Sclar | 10%+ Owner | X | +2,093,022 | — |
| 2025-08-14 | 19 Promis Title | — | X | −359,400 deriv. | — |
| 2025-08-14 | Michael S Gordon | — | X | −359,400 deriv. | — |
| 2025-08-14 | Michael S Gordon | — | J | −48,333 | — |
| 2025-07-29 | Michael S Gordon | 10%+ Owner | X | +359,400 | — |
| 2025-07-29 | 19 Promis Title | 10%+ Owner | X | +359,400 | — |
| 2025-07-02 | Michael S Gordon | 10%+ Owner | Sell | −93,223 | — |
| 2025-06-16 | Eugene Williams | Director | A | +20,000 deriv. | — |
| 2025-06-16 | Patrick D. Kirwin | Director | A | +20,000 deriv. | — |
| 2025-06-16 | Josh Mandel-Brehm | Director | A | +20,000 deriv. | — |
| 2025-06-16 | Madge K. Shafmaster | Director | A | +20,000 deriv. | — |
| 2025-06-16 | William W Wyman | Director | A | +20,000 deriv. | — |
| 2025-02-12 | Neil Cashman | Chief Scientific Officer | Buy | +15,000 | +$14.60K |
| 2024-11-20 | Larry Douglas Altstiel | Chief Medical Officer | A | +175,000 deriv. | — |
| 2024-11-20 | Neil Cashman | Chief Scientific Officer | A | +200,000 deriv. | — |
| 2024-11-20 | Max A. Milbury | Principal Accounting Officer | A | +70,000 deriv. | — |
| 2024-11-20 | Johanne Kaplan | Chief Development Officer | A | +175,000 deriv. | — |
| 2024-10-10 | Neil K Warma | Chief Executive Officer | A | +1,634,460 deriv. | — |
| 2024-10-07 | Eugene Williams | Director | A | +40,000 deriv. | — |
| 2024-10-07 | Josh Mandel-Brehm | Director | A | +40,000 deriv. | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Ally Bridge Group (NY) LLC | 10%+ Owner | 943,090 | $7.60M |
| Jeremy M. Sclar | 10%+ Owner | 123,111 | $992.27K |
| Jeremy M. Sclar 2012 Irrevocable Family Trust | 10%+ Owner | 92,604 | $746.39K |
| 19 Promis Title | 10%+ Owner | 87,817 | $707.81K |
| Eugene Williams | Director | 12,397 | $99.92K |
| Patrick D. Kirwin | Director | 9,788 | $78.89K |
| Max A. Milbury | Principal Accounting Officer | 8,409 | $67.78K |
| Johanne Kaplan | Chief Development Officer | 6,221 | $50.14K |
| Neil K Warma | Chief Executive Officer | 6,183 | $49.83K |
| Neil Cashman | Chief Scientific Officer | 5,196 | $41.88K |
| Madge K. Shafmaster | Director | 2,733 | $22.03K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the PMN quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.